Mayo Clinic-backed Seres has raised its third funding round in just over a year and could go public as early as next year.
US-based biotechnology company Seres Health has secured $48m in a series C round backed entirely by undisclosed public healthcare investors, Xconomy reported on Tuesday.
Seres raised $10m in a June 2014 series B round that included healthcare researcher Mayo Clinic, Enso Ventures and Flagship Ventures. Flagship previously backed Seres’ November 2013 series A round, which raised $10.5m.
Seres is developing a cure for a fatal bacterial infection called clostridium difficile, a bowel infection that occurs in people with a damaged…
